Abstract 387P
Background
Preliminary data suggest that combining savolitinib (AZD6094, HMPL-504, volitinib), a potent and highly selective MET-tyrosine kinase inhibitor (TKI), with osimertinib, a 3rd generation, irreversible, oral epidermal growth factor receptor (EGFR) TKI that potently and selectively inhibits both EGFR mutations (EGFRm) and EGFR T790M, may overcome MET-driven resistance to EGFR-TKIs. The maximum tolerated dose (MTD) of savolitinib regimens in Japanese pts was evaluated in Part C of the phase Ib, multi-arm, open-label, multicenter TATTON study (NCT02143466).
Methods
Two dose-finding cohorts of pts (≥20 years) received savolitinib monotherapy (pts with advanced solid malignancies; savolitinib 400/600 mg once daily [QD]) or savolitinib/osimertinib combination therapy (pts with EGFRm non-small cell lung cancer [NSCLC] who progressed on 1st/2nd-generation EGFR-TKI; osimertinib 80 mg + savolitinib 300/400/600 mg QD). Primary endpoints were safety/tolerability and to define the combination dose(s) for further clinical evaluation. Secondary endpoints for combination included evaluation of tumor response.
Results
Seventeen pts received savolitinib monotherapy (400 mg, n=7/17; 600 mg, n=10/17) and 12 received the combination (savolitinib dose 300 mg, n=2/12; 400 mg, n=6/12; 600 mg, n=4/12). Serious adverse events (AE) were reported in 5/17 and 3/12 of pts, and AEs possibly causally related to savolitinib leading to its discontinuation were reported in 3/17 and 6/12 respectively. Dose-limiting toxicities data are included in the table, all except one were reversible. Pts receiving the combination (across doses) had an objective response rate of 42% (95% confidence interval 15.2, 72.3).
Conclusions
The MTD of savolitinib was 400 mg QD in both monotherapy and combination cohorts. Preliminary data demonstrate an acceptable safety profile for savolitinib and suggest antitumor activity in combination with osimertinib in Japanese pts with EGFRm NSCLC Table: 387P
Dose | Evaluable patients with DLT | DLT* |
Monotherapy | ||
Savolitinib 400 mg | 0/6 | |
Savolitinib 600 mg | 3/9 | Grade 3 ALT increase, Grade 3 AST increase |
Grade 4 ALT increase, Grade 4 AST increase | ||
Grade 4 drug-induced liver injury# | ||
Combination therapy | ||
Savolitinib 300 mg + Osimertinib 80 mg | 0/2 | |
Savolitinib 400 mg + Osimertinib 80 mg | 1/6 | Grade 2 fatigue, Grade 2 nausea, Grade 2 myalgia |
Savolitinib 600 mg + Osimertinib 80 mg | 3/4 | Grade 2 pyrexia† |
Grade 3 skin reaction | ||
Grade 3 anaphylactic shock† |
*n=1 for all events #Not recovered/not resolved †Guidelines are now in place regarding hypersensitivity-related AEs ALT, alanine aminotransferase; AST, aspartate aminotransferase; DLT, Dose-limiting toxicity
.Clinical trial identification
NCT02143466.
Editorial acknowledgement
Bernadette Tynan, MSc, of Ashfield Healthcare Communications, Macclesfield, UK, for medical writing support that was funded by AstraZeneca, Cambridge, UK, in accordance with Good Publications Practice (GPP3) guidelines.
Legal entity responsible for the study
AstraZeneca.
Funding
AstraZeneca.
Disclosure
T. Hirashima: Honoraria (self), Research grant/Funding (self): Ono Pharmaceutical Co. Ltd; Honoraria (self), Research grant/Funding (self): Lilly Japan Co. Ltd.; Honoraria (self), Research grant/Funding (self): AstraZeneca Co. Ltd.; Honoraria (self), Research grant/Funding (self): Taiho Pharmaceutical Co. Ltd.; Honoraria (self), Research grant/Funding (self): Chugai Pharmaceutical Co. Ltd.; Honoraria (self), Research grant/Funding (self): MSD Oncology Co.; Honoraria (self), Research grant/Funding (self): Boehringer Ingelheim; Research grant/Funding (self): Merck Serono Co. Ltd. K. Yoh: Honoraria (self): Chugai Pharma; Honoraria (self): AstraZeneca; Honoraria (self): Lilly Japan; Honoraria (self): Novartis; Honoraria (self): Kirin; Honoraria (self): Bristol-Myers Squibb Japan; Honoraria (self): Taiho. H. Saka: Honoraria (self), Research grant/Funding (self): AstraZeneca. T. Kurata: Honoraria (self), Research grant/Funding (self): AstraZeneca; Honoraria (self): Eli lilly; Honoraria (self), Research grant/Funding (self): MSD; Honoraria (self): Ono; Honoraria (self): Boehringer Ingelheim; Honoraria (self): Chugai; Honoraria (self), Research grant/Funding (self): Bristol-Myers; Research grant/Funding (self): Takeda; Research grant/Funding (self): Novartis. Y. Ohe: Honoraria (self), Advisory/Consultancy, Research grant/Funding (self): AstraZeneca, Chugai, ONO, Bristol-Myers Squibb; Research grant/Funding (self): Takeda; Advisory/Consultancy, Research grant/Funding (self): Kyorin; Advisory/Consultancy: Celltrion; Advisory/Consultancy: Amgen; Advisory/Consultancy: Nippon Kayaku; Honoraria (self): Eli Lilly; Honoraria (self): Boehringer Ingelheim; Honoraria (self): Bayer; Honoraria (self), Research grant/Funding (self): Pfizer; Honoraria (self): MSD; Honoraria (self), Research grant/Funding (self): Taiho; Honoraria (self): Nippon Kayaku; Honoraria (self): Kyowa Hakko Kirin; Research grant/Funding (self): Lilly; Research grant/Funding (self): Dainippon- Sumitomo; Research grant/Funding (self): Novartis; Research grant/Funding (self): Ignyta; Research grant/Funding (self): Kissei; Research grant/Funding (self): Daiichi-Sankyo, Janssen, Loxo. T. Hida: Honoraria (self): Ono Pharmaceutical; Honoraria (self): Chugai Pharmaceutical; Honoraria (self): AstraZeneca; Honoraria (self): Bristol-Meyers Squibb; Honoraria (self): MSD; Honoraria (self): Pfizer; Honoraria (self): Novartis. A. Mellemgaard: Full/Part-time employment: AstraZeneca. R.B. Verheijen: Shareholder/Stockholder/Stock options, Full/Part-time employment: AstraZeneca; Full/Part-time employment: Johnson&Johnson; Shareholder/Stockholder/Stock options: Aduro Biotech. X. Ou: Full/Part-time employment, Contracted with AstraZeneca through Phastar: AstraZeneca. M. Hayama, K. Sugibayashi: Shareholder/Stockholder/Stock options, Full/Part-time employment: AstraZeneca. G. Oxnard: Honoraria (self): Foundation Medicine; Honoraria (self): Guardant Health; Honoraria (self): Sysmex; Advisory/Consultancy: AbbVie; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: DropWorks; Advisory/Consultancy: GRAIL; Advisory/Consultancy: Illumina; Advisory/Consultancy: Inviata; Advisory/Consultancy: Janssen; Advisory/Consultancy: Loxo; Advisory/Consultancy: Takeda; Licensing/Royalties, DCFI patent describing blood-based cancer monitoring: DFCI; Full/Part-time employment, Commencing June 15th: Foundation Medicine.
Resources from the same session
94P - Prognostic influence of mean platelet volume on stage III rectal cancer patients: A tertiary cancer center study
Presenter: Pavan Jonnada
Session: e-Poster Display Session
95P - Prognosis of Japanese patients with detailed RAS/BRAF mutant colorectal cancer
Presenter: Tatsuki Ikoma
Session: e-Poster Display Session
96P - Early-onset colorectal cancer prognosis, conflict resolution, review of literature and meta-analysis
Presenter: Ereny Poles
Session: e-Poster Display Session
97P - A population-based study to assess the associations of rural residence and low socioeconomic status (SES) with cardiovascular disease (CVD) in patients with colorectal cancer (CRC)
Presenter: Atul Batra
Session: e-Poster Display Session
98P - Operational challenges of an Asian Pacific (APAC) academic oncology clinical trial
Presenter: Daphne Day
Session: e-Poster Display Session
99P - Development of a qRT-PCR-based diagnostic test to identify colorectal cancer patients with recurrent R-Spondin gene fusions
Presenter: Veronica Diermayr
Session: e-Poster Display Session
100P - Individualized treatment of advanced digestive system tumour guided by PDTX mouse model: A multicenter trial
Presenter: yuan cheng
Session: e-Poster Display Session
101P - HIF1-α depletion overcomes resistance to oxaliplatin in colorectal cancer via ERK signalling pathway
Presenter: Se Jun Park
Session: e-Poster Display Session
102P - Colorectal cancer organoids culture exploits new neoadjuvant therapy resistance mechanisms and therapeutic targets
Presenter: Yun Deng
Session: e-Poster Display Session
103P - Comprehensive genomic landscape in younger and older Chinese patients with colorectal cancer
Presenter: Huina Wang
Session: e-Poster Display Session